Navigation Links
New protein discovered by Hebrew University researchers

d thus enhance the effectiveness of chemotherapy. This selective penetration is based on the fact that the blood vessels which feed tumors are considerably more porous than those reaching healthy cells. Therefore, the units of SP-1 carrying the drug would invade only the tumor-feeding blood vessels and not normal ones. More recently, the three-dimensional structure of the protein was deciphered by x-ray crystallography. The research on this was published in the Journal of Biological Chemistry issue of December 2004, authored by graduate student Orna Dgany, Prof. Altman and Prof. Shoseyov, in cooperation with Dr. Orna Almog of Ben-Gurion University of the Negev and Dr. Sharon Wolf of the Weizmann Institute of Science and other researchers. Prof. Altman and Prof. Shoseyov are the scientific founders of the biotech start-up company Fulcrum SP Ltd. that is developing the SP-1 protein for cancer drug delivery and other applications.
'"/>

Source:Hebrew University of Jerusalem


Page: 1 2

Related biology news :

1. New, automated tool successfully classifies and relates proteins in unprecedented way
2. New binding target for oncogenic viral protein
3. Controversial drug shown to act on brain protein to cut alcohol use
4. Timing is everything: First step in protein building revealed
5. UWs Rosetta software to unlock secrets of many human proteins
6. Researchers find how protein allows insects to detect and respond to pheromones
7. Signaling protein builds bigger, better bones in mice
8. Ancient olfaction protein is shared by many bugs, offering new pest control target
9. Automatic extraction of gene/protein biological functions from biomedical text
10. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
11. Scientists develop new color-coded test for protein folding
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New protein discovered Hebrew University researchers

(Date:7/30/2014)... major interest in neuroscience. A large number of ... of Wallerian degeneration: transcription factor activation, immune response, ... responses in the distal segment of the sciatic ... in gene expression between the proximal and distal ... from Nantong University, China used microarrays to analyze ...
(Date:7/30/2014)... robust therapies for spinal cord injury (SCI), traumatic brain ... A great deal has been learned over the past ... environmental factors that regulate axon growth, but this large ... available therapeutics. Prof. Lemmon and his team from University ... many root causes, but a consensus is emerging that ...
(Date:7/30/2014)... roughly 3,000 pieces is still in its infant stage. ... be of major significance. "Amazingly often, we are findingin ... amber that we found in Baltic amber," explained Bonn ... amber comes from the Baltic Sea region, which is ... are, e.g., the coastal regions of Mecklenburg, Poland and ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2
... with the heat insulation of leaf litter and soil can ... helping land managers find the best time to use prescribed ... "Acorns inside the leaf litter or in the soil ... Greenberg, Forest Service Southern Research Station (SRS) researcher and lead ...
... Ore. Climate change, habitat destruction, pollution and invasive ... amphibian declines and extinctions, researchers suggest in a new ... in the form of infectious disease. Amphibians are ... range of infectious organisms, including viruses, bacteria and fungi, ...
... from the University of Southampton, which examines how dolphins might ... man-made sonar to detect targets, such as sea mines, in ... to blow ,bubble nets, around schools of fish, which force ... dolphins to pick off. However, such bubble nets would confound ...
Cached Biology News:Leaf litter and soil protect acorns from prescribed fire 2Environmental concerns increasing infectious disease in amphibians, other animals 2Do dolphins think nonlinearly? 2Do dolphins think nonlinearly? 3
(Date:7/30/2014)... Wellesley, MA (PRWEB) July 30, 2014 ... report, Global Markets for Enzymes in Industrial Applications ... to reach to nearly $7.1 billion by 2018, registering ... Maximum growth is estimated to be recorded in the ... the forecast period. , Enzyme technology has influenced almost ...
(Date:7/30/2014)... Md. , July 30, 2014 ... components to interrogate biology, but such devices can ... As such, researchers have looked ... in vitro metabolic engineering to characterize ... a chip. New devices are envisioned to recreate ...
(Date:7/30/2014)... July 30, 2014 Connecticut Center for ... based in East Hartford, Conn., was awarded a Rural ... of a project that will determine the feasibility of ... north-central Connecticut. USDA Rural Development provided $53,000 for CCAT ... the second phase of the feasibility study in fiscal ...
(Date:7/29/2014)... 30, 2014 SoundConnect , ... company, is proud to announce the strategic additions ... in their Boston, Charleston and Atlanta offices. ... increased demand for hosted solutions, collaboration and mobility ... reduce cost. , SoundConnect was founded in 2004, ...
Breaking Biology Technology:Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3SoundConnect Organization and Culture is Evolving 2
... LAIYANG, China, Feb. 17 /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. ... pharmaceutical company with its principal operations in the,People,s Republic ... quarter of its fiscal year 2009 ended December 31, ... Fiscal Year 2009 Highlights, -- Revenue ...
... in the Biotech IndustryFT. LAUDERDALE, Fla., Feb. ... full-service securities broker-dealer and investment bank, is ... Newbridge BioVentures Division ("NBV"). NBV is dedicated ... biotech industry and related investment opportunities for ...
... 17 Human Genome Sciences, Inc. (Nasdaq: ... GSK ) has initiated a Phase 3 clinical trial ... Syncria (R) (albiglutide) in the long-term treatment of ... will receive a $9 million milestone payment in the ...
Cached Biology Technology:Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 2Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 4Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 5Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 6Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 7Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 8Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 9Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 10Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 11Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 12Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 13Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 14Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 15Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 16Newbridge Securities Corporation Forms BioVentures Division 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 4
Human Serpin B5/Maspin Affinity Purified Polyclonal Ab...
... S.J. Allen (1995) This book ... authorities on current issues relating to the ... major advances have been made recently which ... Topics include molecular neuropathology through clinical and ...
Normal human serum, single donor...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
Biology Products: